JW Pharmaceutical announced on the 10th that its first quarter sales recorded 171.3 billion won, an increase of about 11.1% from 154.2 billion won the previous year.
During the same period, operating profit was KRW 21.5 billion, up 42.3% from KRW 14.1 billion in the first quarter last year, and net profit was also KRW 16.8 billion, up 57.8% from KRW 10.6 billion in the same period last year .
Inside and outside the industry, this performance is evaluated to have surpassed the previous industry analysis with high growth such as ‘Libarojet’ and assetization of a phase 3 clinical trial for gout.
